Vitrolife マネジメント

マネジメント基準チェック /24

Vitrolifeの CEO はBronwyn Brophy O´Connorで、 Aug2023年に任命され、の在任期間は 1.25年です。の年間総報酬はSEK 7.44Mで、 74.5%給与と25.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.014%を直接所有しており、その価値は€ 372.50K 。経営陣と取締役会の平均在任期間はそれぞれ1.3年と6.8年です。

主要情報

Bronwyn Brophy O´Connor

最高経営責任者

SEK 7.4m

報酬総額

CEO給与比率	74.5%
CEO在任期間	1.3yrs
CEOの所有権	0.01%
経営陣の平均在職期間	1.3yrs
取締役会の平均在任期間	6.8yrs

経営陣の近況

Recent updates

CEO報酬分析

Vitrolife の収益と比較して、Bronwyn Brophy O´Connor の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-SEK 4b
Jun 30 2024	n/a	n/a	-SEK 4b
Mar 31 2024	n/a	n/a	-SEK 4b
Dec 31 2023	SEK 7m	SEK 6m	-SEK 4b

報酬と市場: Bronwynの総報酬 ($USD 673.62K ) は、 German市場 ($USD 1.90M ) の同様の規模の企業の平均を下回っています。

報酬と収益: Bronwynの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Bronwyn Brophy O´Connor (50 yo)

1.3yrs

在職期間

SEK 7,439,000

報酬

Ms. Bronwyn Brophy O´Connor is President and Chief Executive Officer at Vitrolife AB (publ) since joining from August 01, 2023. She has an impressive track record as a leader of global Life science and Med...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Bronwyn Brophy O´Connor	CEO & President	1.3yrs	SEK 7.44m	0.014% € 372.5k
Patrik Tolf	Chief Financial Officer	2.8yrs	データなし	0.0096% € 250.2k
Claus Bisgaard	Senior Vice President of Technologies	no data	データなし	0.00028% € 7.3k
Guillermo Ferrando	Vice President Strategy & Corporate development	1.8yrs	データなし	データなし
Olivia Natens	Senior Vice President of Sales & Marketing	less than a year	データなし	データなし
Frank Pettersson	Acting Senior Vice President of HR & Sustainability	1.1yrs	データなし	0.0013% € 34.1k
Rickard Ericsson	Senior Vice President of Consumables	less than a year	データなし	0.0061% € 159.8k
Ricardo Capella	Senior Vice President Genetic Services	2.8yrs	データなし	0.0044% € 115.5k

1.3yrs

平均在職期間

53.5yo

平均年齢

経験豊富な経営陣: VTFNの経営陣は経験豊富とはみなされません ( 1.3年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Henrik Blomquist	Director	5.5yrs	SEK 883.00k	0.0081% € 211.7k
Jon Sigurdsson	Chairman of the Board	9.8yrs	SEK 16.30m	0.022% € 585.2k
Lars Holmqvist	Independent Director	6.8yrs	SEK 450.00k	データなし
Pia Marions	Independent Director	11.6yrs	SEK 500.00k	0.0037% € 96.2k
Karen Soerensen	Independent Director	4.4yrs	SEK 500.00k	データなし

6.8yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: VTFNの取締役会は経験豊富であると考えられます ( 6.8年の平均在任期間)。

Vitrolife マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Vitrolife AB (Publ) Announces Election Committee Appointments

Vitrolife AB (publ) Announces Election Committee Appointments

Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice President

Insufficient new directors

Vitrolife AB Announces Board Changes

Chief Financial Officer recently bought €47k worth of stock

Recent updates

Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025

Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026

Third quarter 2024 earnings released: EPS: kr0.86 (vs kr0.90 in 3Q 2023)

Vitrolife AB (Publ) Announces Election Committee Appointments

Now 21% overvalued after recent price rise

Now 21% overvalued after recent price rise

Vitrolife AB (publ) to Report Q3, 2025 Results on Oct 29, 2025

Second quarter 2024 earnings released: EPS: kr1.06 (vs kr0.78 in 2Q 2023)

Now 19% undervalued after recent price drop

Now 19% undervalued after recent price drop

Now 20% undervalued after recent price drop

Vitrolife AB (publ) (OM:VITR) acquired Stb Zorg B.V.

Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million.

Vitrolife AB (Publ) Approves Dividend for the Financial Year 2023

Upcoming dividend of kr1.00 per share

Now 24% undervalued

First quarter 2024 earnings released: EPS: kr0.85 (vs kr0.74 in 1Q 2023)

Dividend of kr1.00 announced

Full year 2023 earnings released: kr28.44 loss per share (vs kr2.91 profit in FY 2022)

Vitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023

Now 20% undervalued

Third quarter 2023 earnings released: EPS: kr0.90 (vs kr0.80 in 3Q 2022)

Vitrolife AB (publ) Announces Election Committee Appointments

Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice President

Insufficient new directors

Vitrolife AB Announces Board Changes

Investor sentiment deteriorates as stock falls 18%

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: kr0.78 (vs kr0.96 in 2Q 2022)

Vitrolife AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 15%

Chief Financial Officer recently bought €47k worth of stock

Upcoming dividend of kr0.85 per share at 0.4% yield

Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021)

Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021)

Vitrolife AB (publ) Proposes Dividend for 2022

Vitrolife AB (publ) Announces Executive Changes

Third quarter 2022 earnings released: EPS: kr0.80 (vs kr0.89 in 3Q 2021)

Vitrolife AB (publ) to Report First Half, 2023 Results on Jul 14, 2023

Vitrolife AB (publ) Announces Election Committee Appointments

Investor sentiment deteriorated over the past week

Now 20% undervalued after recent price drop

Vitrolife AB (Publ) Announces Retirement of Thomas Axelsson as CEO

Second quarter 2022 earnings released: EPS: kr0.96 (vs kr0.79 in 2Q 2021)

Vitrolife AB (publ), Annual General Meeting, Apr 27, 2023

Chief Financial Officer recently bought €48k worth of stock

First quarter 2022 earnings released: EPS: kr0.61 (vs kr1.09 in 1Q 2021)

First quarter 2022 earnings released: EPS: kr0.61 (vs kr1.09 in 1Q 2021)

Upcoming dividend of kr0.80 per share

Vitrolife AB (Publ) Proposes Dividend

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Vitrolife AB (Publ) Proposes Dividend

Third quarter 2021 earnings released: EPS kr0.89 (vs kr0.81 in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.79 (vs kr0.11 in 2Q 2020)

Vitrolife AB (publ) Approves Dividend for the Financial Year 2020

First quarter 2021 earnings released: EPS kr1.09 (vs kr0.73 in 1Q 2020)

Upcoming dividend of kr0.80 per share

Full year 2020 earnings released: EPS kr2.64 (vs kr3.53 in FY 2019)

Full year 2020 earnings released: EPS kr2.64 (vs kr3.53 in FY 2019)

Revenue misses expectations

New 90-day high: €22.60

Vitrolife AB (publ) to Report Fiscal Year 2020 Results on Feb 10, 2021

New 90-day low: €20.14

Third quarter 2020 earnings released: EPS kr0.81

Revenue beats expectations

Vitrolife AB (publ) to Report Fiscal Year 2020 Results on Mar 30, 2021

Vitrolife AB (publ) to Report Q1, 2021 Results on Apr 22, 2021

New 90-day low: €20.16

マネジメント基準チェック /24